{"id":41349,"date":"2023-10-11T12:55:17","date_gmt":"2023-10-11T12:55:17","guid":{"rendered":"https:\/?p=41349"},"modified":"2023-10-11T12:55:17","modified_gmt":"2023-10-11T12:55:17","slug":"nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/","title":{"rendered":"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector"},"content":{"rendered":"<p><span data-preserver-spaces=\"true\">The shares of dialysis service providers faced a significant dip during pre-market trading on Wednesday. Novo Nordisk (<\/span><a class=\"editor-rtfLink\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/NVO\" target=\"_blank\" rel=\"noopener\"><span data-preserver-spaces=\"true\">NVO:NYE<\/span><\/a><span data-preserver-spaces=\"true\">), a prominent healthcare company, delivered a blow to the market by announcing the early termination of its Ozempic study. The decision came after an interim analysis, compelling NVO to halt testing its diabetes drug, Ozempic, as a potential treatment for kidney failure. This article will discuss the effects of these events on the NVO stock forecast.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><span data-preserver-spaces=\"true\">Abandonment of the Ozempic Study:<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">Novo Nordisk announced that the FLOW trial, examining semaglutide&#8217;s effectiveness in kidney failure and type 2 diabetes, ended prematurely based on the Data Monitoring Committee&#8217;s recommendation following favorable interim analysis results.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><span data-preserver-spaces=\"true\">Impact on Dialysis Service Providers:<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">A report from Reuters featured insights from Citi analyst Veronika Dubajova, who underlined the potential adverse effects of terminating the trial. She noted that the discontinuation of Ozempic could negatively influence dialysis service companies such as DaVita (<\/span><a class=\"editor-rtfLink\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/DVA\" target=\"_blank\" rel=\"noopener\"><span data-preserver-spaces=\"true\">DVA:NYE<\/span><\/a><span data-preserver-spaces=\"true\">) and Fresenius (<a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/FMS\">FMS:NYE<\/a>), primarily because drugs like Ozempic might affect the size of the relevant patient population over time.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><span data-preserver-spaces=\"true\">NVO Stock Forecast:<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">The average target price is USD 152.50 for Novo Nordisk. The consensus among analysts is notably favorable, with an average rating of &#8220;Strong Buy.&#8221; Stock Target Advisor&#8217;s analysts are &#8220;slightly bullish.&#8221; This classification is based on nine positive and five negative signals.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/NVO\" target=\"_blank\" rel=\"noopener\">NVO Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"NVO\" data-theme=\"wt_bg_trans\" data-uid=\"111039659665269b16527d665269b16527d7\" data-width=\"1200\" >\n\t\t<\/script><\/p>\n<\/div>\n<h2><span data-preserver-spaces=\"true\">Stock Outlook:<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">At the last closing, the stock price was USD 93.01. This price has changed by +5.96% over the past week, -52.40% over the past month, and +79.12% over the last year.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><span data-preserver-spaces=\"true\">Conclusion:<\/span><\/h2>\n<p><span data-preserver-spaces=\"true\">The abrupt cessation of Novo Nordisk&#8217;s Ozempic study is reshaping the healthcare sector. Dialysis providers like DaVita and Fresenius face uncertainty. Financial markets react, altering investment strategies. Novo Nordisk&#8217;s stock forecast remains positive, securing its future.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The shares of dialysis service providers faced a significant dip during pre-market trading on Wednesday. Novo Nordisk (NVO:NYE), a prominent healthcare company, delivered a blow&#8230;<\/p>\n","protected":false},"author":12,"featured_media":41354,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[3830],"class_list":["post-41349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","tag-biotechnology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector<\/title>\n<meta name=\"description\" content=\"NVO&#039;s Ozempic kidney study suspension impacted pre-market shares for dialysis providers like DVA and FMS. Read more for NVO stock forecast.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector\" \/>\n<meta property=\"og:description\" content=\"NVO&#039;s Ozempic kidney study suspension impacted pre-market shares for dialysis providers like DVA and FMS. Read more for NVO stock forecast.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-11T12:55:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/10\/untitled-design-2023-10-11T173411.857.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Maryam Nasir\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maryam Nasir\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/\"},\"author\":{\"name\":\"Maryam Nasir\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/b727a9bd19dbc33ef5e25bc036d45075\"},\"headline\":\"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector\",\"datePublished\":\"2023-10-11T12:55:17+00:00\",\"dateModified\":\"2023-10-11T12:55:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"keywords\":[\"Biotechnology\"],\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/\",\"name\":\"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2023-10-11T12:55:17+00:00\",\"dateModified\":\"2023-10-11T12:55:17+00:00\",\"description\":\"NVO's Ozempic kidney study suspension impacted pre-market shares for dialysis providers like DVA and FMS. Read more for NVO stock forecast.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/b727a9bd19dbc33ef5e25bc036d45075\",\"name\":\"Maryam Nasir\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/46d7f89a00c879dd9d7f38b422780e56768de51a30d1bf12093340c9885cc15f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/46d7f89a00c879dd9d7f38b422780e56768de51a30d1bf12093340c9885cc15f?s=96&d=mm&r=g\",\"caption\":\"Maryam Nasir\"},\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/maryam\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector","description":"NVO's Ozempic kidney study suspension impacted pre-market shares for dialysis providers like DVA and FMS. Read more for NVO stock forecast.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/","og_locale":"en_US","og_type":"article","og_title":"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector","og_description":"NVO's Ozempic kidney study suspension impacted pre-market shares for dialysis providers like DVA and FMS. Read more for NVO stock forecast.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2023-10-11T12:55:17+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/10\/untitled-design-2023-10-11T173411.857.png","type":"image\/png"}],"author":"Maryam Nasir","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Maryam Nasir","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/"},"author":{"name":"Maryam Nasir","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/b727a9bd19dbc33ef5e25bc036d45075"},"headline":"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector","datePublished":"2023-10-11T12:55:17+00:00","dateModified":"2023-10-11T12:55:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"keywords":["Biotechnology"],"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/","name":"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2023-10-11T12:55:17+00:00","dateModified":"2023-10-11T12:55:17+00:00","description":"NVO's Ozempic kidney study suspension impacted pre-market shares for dialysis providers like DVA and FMS. Read more for NVO stock forecast.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/nvo-stock-forecast-ozempic-study-halt-impacts-dialysis-sector\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"NVO Stock Forecast: Ozempic Study Halt Impacts Dialysis Sector"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/b727a9bd19dbc33ef5e25bc036d45075","name":"Maryam Nasir","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/46d7f89a00c879dd9d7f38b422780e56768de51a30d1bf12093340c9885cc15f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/46d7f89a00c879dd9d7f38b422780e56768de51a30d1bf12093340c9885cc15f?s=96&d=mm&r=g","caption":"Maryam Nasir"},"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/maryam\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/41349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=41349"}],"version-history":[{"count":4,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/41349\/revisions"}],"predecessor-version":[{"id":41360,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/41349\/revisions\/41360"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/41354"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=41349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=41349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=41349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}